Oruka Therapeutics Announces Strong Week 16 Data for ORKA-001 in Phase 2a Psoriasis Trial

Key Points for Investors

• ORKA-001 achieves 63.5% PASI 100 (complete skin clearance) at Week 16 in EVERLAST-A Phase 2a trial for moderate-to-severe plaque psoriasis
• Favorable safety profile, comparable to placebo and consistent with the IL-23p19 inhibitor class
• Updated pharmacokinetic data supports potential for once-yearly dosing
• Longer-term efficacy data expected in 2H 2026; Phase 2b results anticipated in 2027
• Management to host investor webcast for further details

Detailed Report

Oruka Therapeutics, Inc. (Nasdaq: ORKA) has reported highly positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life extended IL-23p19 monoclonal antibody designed for the treatment of moderate-to-severe plaque psoriasis.

According to Chief Medical Officer Dr. Joana Goncalves, the data “reached the top end” of expectations for efficacy, tolerability, and potential for lasting response. Dr. Bruce Strober, lead investigator and Clinical Professor of Dermatology at Yale, stated that the results, if confirmed with infrequent dosing, could represent a major advance in the field and make ORKA-001 a preferred option for moderate-to-severe psoriasis patients.

Efficacy Results

• In the double-blind, placebo-controlled Phase 2a EVERLAST-A trial (84 patients, randomized 3:1, 600 mg ORKA-001 at weeks 0 and 4 vs. placebo), 63.5% (40/63) of ORKA-001 treated participants achieved PASI 100 (complete skin clearance) at Week 16.
• Identical results were observed for IGA 0 (Investigator’s Global Assessment of “clear”).
• Other key results:
  • 83% achieved PASI 90 at Week 16 (near-complete skin clearance)
  • 84% achieved IGA 0/1 at Week 16
  • In the placebo group, only one patient reached these endpoints, consistent with historical controls.
• These efficacy rates are numerically higher than other IL-23p19 inhibitors and comparable to the highest reported for any mechanism of action in plaque psoriasis.

Safety Data

• ORKA-001 demonstrated a favorable safety profile, with no serious treatment-emergent adverse events (TEAEs) in the active group. Notably, the only severe TEAE occurred in the placebo group.
• Most TEAEs were mild; overall rates were 51% (ORKA-001) and 57% (placebo).
• The only TEAE occurring in ≥5% of subjects was upper respiratory tract infection (19% for ORKA-001, 14% for placebo).
• No injection site reactions were reported.

Pharmacokinetic and Pharmacodynamic Insights

• Phase 1 data shows that a single 600 mg dose of ORKA-001 maintains drug levels above effective trough concentrations for a full year, with sustained inhibition of IL-23 signaling throughout that period.
• No impact from anti-drug antibodies was observed in either Phase 1 or EVERLAST-A trials.
• These findings support the potential for once-yearly dosing, which would be a significant differentiator in the market.

Upcoming Milestones

• Longer-term data from EVERLAST-A, including 28-week efficacy for all patients and 52-week follow-up in a subset, is expected in the second half of 2026.
• The ongoing Phase 2b EVERLAST-B trial is progressing, with results anticipated in 2027.

Strategic and Market Implications

The strong efficacy, safety, and differentiated dosing potential of ORKA-001 position Oruka Therapeutics as a key emerging player in the dermatology and immunology space. Should longer-term data confirm these results, ORKA-001 could become the preferred biologic therapy for moderate-to-severe plaque psoriasis, with potential to disrupt existing treatment paradigms and drive significant commercial value.

Investors should note that data supporting annual or twice-yearly dosing could be highly attractive in terms of patient compliance, payer acceptance, and competitive differentiation. Any changes in the safety, efficacy, or dosing profile in upcoming trials may materially impact Oruka’s valuation and commercial outlook.

Conference Call and Webcast

Oruka will be hosting a live webcast to discuss the EVERLAST-A results. Details and the replay are available on the investor section of the company website.

About Oruka Therapeutics

Oruka Therapeutics develops novel biologics targeting chronic skin diseases such as plaque psoriasis, aiming to maximize disease clearance with infrequent dosing. The company’s pipeline is based on proprietary antibodies engineered in partnership with Paragon Therapeutics.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should consult Oruka Therapeutics’ filings with the SEC and consider all risk factors before making investment decisions. The author assumes no responsibility for actions taken based on this article.

View Oruka Therapeutics, Inc. Historical chart here